VAXX - Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

• Vaxxinity ( NASDAQ: VAXX ) on Monday said it had started a rolling submission to UK's drug regulator for conditional marketing approval of its UB-612 COVID-19 vaccine for use as a booster dose.
• The shot is currently being evaluated in a phase 3 trial as a booster dose for subjects who have received primary immunization with mRNA, adenovirus vector or inactivated virus vaccines, VAXX said in a statement .
• VAXX reiterated its expectation of having a readout from the late-stage trial in Q4 2022.
• "Authorizations by stringent regulatory authorities such as the (UK's Medicines and Healthcare products Regulatory Agency) could open the pathway for UB-612 to reach countries with high unmet needs," VAXX CEO Mei Mei Hu said.
• Class A shares of VAXX were 0.5% lower at $2.15 in morning trading.

For further details see: